Kimberly-Clark Seeks EU Approval for $40 Billion Kenvue Acquisition

Key Facts

1Kimberly-Clark has formally requested EU regulatory approval for its proposed $40 billion takeover of Kenvue.

In a move reflecting the accelerating pace of consolidation within the global consumer goods sector, Kimberly-Clark has formally requested EU regulatory approval for its proposed acquisition of Kenvue. The $40 billion mega-merger aims to bring Kenvue, the manufacturer of Tylenol, under Kimberly-Clark's umbrella. This filing with the European Commission is a mandatory regulatory step required to advance the combination of their extensive consumer health and personal care portfolios.

This development occurs amidst a mixed backdrop for global consumer markets, where market data from August 21, 2026, showed Canadian retail sales growing by 5.2% annually, while Eurozone consumer confidence remained pressured at -15.5. The formal submission for antitrust clearance represents a significant milestone for the deal, moving the $40 billion transaction into a critical phase of regulatory scrutiny within the European Union.

At the close of August 27, 2026, Kenvue (KVUE) shares stood at $19.20, having traded between a day low of $18.99 and a high of $19.25. Investors will now look toward the European Commission for initial feedback on the merger, while also monitoring broader consumer sentiment indicators to gauge the long-term viability of such large-scale integrations in the current economic climate.